Market open
Annexon/$ANNX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Annexon
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Ticker
$ANNX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
84
Website
Annexon Metrics
BasicAdvanced
$452M
-
-$1.00
1.10
-
Price and volume
Market cap
$452M
Beta
1.1
52-week high
$8.40
52-week low
$3.86
Average daily volume
1.5M
Financial strength
Current ratio
17.175
Quick ratio
16.967
Long term debt to equity
8.195
Total debt to equity
8.93
Management effectiveness
Return on assets (TTM)
-28.24%
Return on equity (TTM)
-48.12%
Valuation
Price to book
1.35
Price to tangible book (TTM)
1.35
Price to free cash flow (TTM)
-4.734
Growth
Earnings per share change (TTM)
-47.36%
3-year earnings per share growth (CAGR)
-30.98%
What the Analysts think about Annexon
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Annexon stock.
Annexon Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Annexon Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Annexon News
AllArticlesVideos
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire·2 weeks ago
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Annexon stock?
Annexon (ANNX) has a market cap of $452M as of January 24, 2025.
What is the P/E ratio for Annexon stock?
The price to earnings (P/E) ratio for Annexon (ANNX) stock is 0 as of January 24, 2025.
Does Annexon stock pay dividends?
No, Annexon (ANNX) stock does not pay dividends to its shareholders as of January 24, 2025.
When is the next Annexon dividend payment date?
Annexon (ANNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Annexon?
Annexon (ANNX) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.